1. Home
  2. CXAI vs PLUR Comparison

CXAI vs PLUR Comparison

Compare CXAI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.39

Market Cap

17.8M

Sector

Technology

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$3.54

Market Cap

34.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXAI
PLUR
Founded
N/A
2001
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
34.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CXAI
PLUR
Price
$0.39
$3.54
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
2.8M
44.2K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,222,000.00
$1,326,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
$70.21
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
121.74
52 Week Low
$0.36
$2.82
52 Week High
$2.54
$7.13

Technical Indicators

Market Signals
Indicator
CXAI
PLUR
Relative Strength Index (RSI) 40.40 48.89
Support Level $0.37 $2.82
Resistance Level $0.42 $3.72
Average True Range (ATR) 0.06 0.33
MACD 0.00 0.02
Stochastic Oscillator 11.50 52.73

Price Performance

Historical Comparison
CXAI
PLUR

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: